Exosomal miRNAs: biological properties and therapeutic potential

Guoku Hu1,2, Kristen M. Drescher1 and Xian-Ming Chen1*  

1 Department of Medical Microbiology and Immunology, Creighton University Medical Center, Omaha, NE, USA  
2 College of Materials and Chemistry and Chemical Engineering, Chengdu University of Technology, Chengdu, China

MicroRNAs (miRNAs), small non-coding regulatory RNAs that regulate gene expression at the post-transcriptional level, are master regulators of a wide array of cellular processes. Altered miRNA expression could be a determinant of disease development and/or progression and manipulation of miRNA expression represents a potential avenue of therapy. Exosomes are cell-derived extracellular vesicles that promote cell–cell communication and immunoregulatory functions. These “bioactive vesicles” shuttle various molecules, including miRNAs, to recipient cells. Inappropriate release of miRNAs from exosomes may cause significant alterations in biological pathways that affect disease development, supporting the concept that miRNA-containing exosomes could serve as targeted therapies for particular diseases. This review briefly summarizes recent advances in the biology, function, and therapeutic potential of exosomal miRNAs.

INTRODUCTION

Exosomes are small (30–90 nm) extracellular vesicles derived from the multivesicular body (MVB) sorting pathway. These vesicles are produced by a wide variety of cell types including reticulocytes, epithelial cells, neurons, and tumor cells (Thery et al., 2009). Exosomes have been isolated from bronchoalveolar lavage, urine, serum, bile, and breast milk (Thery, 2011). Although previously considered to be cellular waste products (Thery, 2011), recent studies have demonstrated that exosomes are “bioactive vesicles” that promote intercellular communication and immunoregulatory processes by shuttling molecules between cells (Thery et al., 2009; Pegtel et al., 2010).

One of the most recent exciting findings is that microRNAs (miRNAs) exist in exosomes and these exosomal miRNAs can be functionally delivered to target cells (Montecalvo et al., 2012). miRNAs are small non-coding regulatory RNAs that bind to complementary sequences in the 3′-untranslated region (3′UTR) of target mRNAs, leading to either translational repression or target degradation of the specific mRNA (Bartel, 2004, 2009). miRNAs play a pivotal regulatory role in diverse biological processes including but not limited to, development and cell signaling, proliferation and differentiation (Bartel, 2004, 2009). While miRNA expression patterns are incompletely defined in most cell types under normal conditions, aberrant expression of certain miRNAs has been described in diverse human diseases, suggesting that miRNAs can be used as biomarkers for disease development and as a potential target of therapy (Jiang et al., 2009). Several publicly available databases (e.g., miR2Disease) have been established which document the relationships between the expression of specific miRNAs and the development and/or progression of specific human diseases (Jiang et al., 2009). Identification of miRNAs key to disease pathogenesis provides new insights into the development of therapeutic targets in the treatment of human diseases, particularly for some forms of cancer. Currently, several approaches to manipulate miRNA function are being studied in clinical trials (Kasinski and Slack, 2011). Because inappropriately released miRNA-containing exosomes have been shown to significantly alter biological pathways integral to disease development (Record et al., 2011), it is postulated that exosomes could be used to deliver therapeutic molecules in a variety of human diseases. Here, we briefly summarize recent advances in the biology, function and therapeutic potential of exosomal miRNAs.

EXOSOMES ARE CELL–CELL MEDIATORS WITH PHYSIOLOGICAL AND PATHOLOGICAL SIGNIFICANCE

Exosomes are the newest family member of “bioactive vesicles.” These bioactive vesicles were originally described during maturation of reticulocytes into erythrocytes. These small vesicles contained the transferrin receptor which is downregulated in mature erythrocytes (Pan and Johnstone, 1983). Exosomes are also secreted by a variety of cell types including mast cells (Laulagnier et al., 2004), B lymphocyte cell lines, dendritic cells (Laulagnier et al., 2004), platelets, astrocyes, neurons, and epithelial cells (Hogan et al., 2009; Zhou et al., 2011). Exosomes enter the circulatory system and bodily fluids and have been detected in plasma, bronchoalveolar lavage, blood, urine, bile (Masyuk et al., 2010), ascites (Rupp et al., 2011), breast milk, and cerebrospinal fluid. Tumor-derived exosomes have been identified in the plasma of patients with lung adenocarcinoma, glioblastoma multiforme, malignant glioma, and ovarian carcinoma ascites (Skog et al., 2008; Rabinowits et al., 2009; Rupp et al., 2011).

The formation and release of exosomes are tightly regulated processes governed by multiple signaling mechanisms. Various stimuli influence exosome secretion including activation of a
variety of receptors including the P2X receptor by ATP on monocytes and neutrophils, the thrombin receptor on platelets, and toll-like receptor-4 (TLR-4) by bacterial lipopolysaccharide (LPS) on dendritic cells (Bhatnagar and Schorey, 2007). Morphological studies suggest that exosomes are derived from the MVB sorting pathway. The MVBs fuse with the plasma membrane and release the vesicles into the extracellular milieu as exosomes. The exosomes consist of a lipid bilayer membrane surrounding a small cytosol that lacks cellular organelles such as mitochondria, lysosomes, endoplasmic reticulum, nucleus, and Golgi apparatus.

The formation and release of exosomes involves contractile machinery that draws opposing membranes together before pinching off the membrane connection and releasing the vesicle into the extracellular space (Cocucci et al., 2009). SNARE (soluble NSF attachment protein receptor) complexes are proposed to be involved in bringing the membranes together in opposition, as there is an energy requirement for the membrane fusion process (Sudhof and Rothman, 2009). SNAREs can be divided into vesicle (v-SNAREs) and target SNAREs (t-SNAREs; Fukuda et al., 2000). The complex begins assembling at the N-terminal region of the SNARE motifs and proceeds toward the C-termini which anchors the interacting proteins in the membranes (Sutton et al., 1998). An intermediate complex composed of SNAP-25 and syntaxin-1, which interacts with synaptobrevin-2 then forms. Recent studies from Thery's group demonstrated that several Rab family proteins, including Rab27a and Rab27b, are key regulators of the exosome secretion pathway (Ostrowski et al., 2010). Several lines of evidence support a role for Rab27a and Rab27b in MVB docking at the plasma membrane. Rab27a silencing increases the size of MVBs; alternatively, Rab27b silencing results in redistribution of the MVBs to the perinuclear region (Ostrowski et al., 2010). Another Rab family member protein, Rab35, is a target of TBC1D10A-C, which regulates exosome secretion and inhibiting Rab35 activity induces intracellular accumulation of endosomal vesicles and impaired exosome secretion (Hsu et al., 2010). Recent studies revealed that exosomes can be released into the extracellular environment by the outward budding and fission of the plasma membrane, a pathway called the exosome and microvesicle (EMV) budding pathway. The progression of the EMV pathway is regulated by multiple processes including the elevation of intracellular calcium and reorganization of the cell’s structural scaffolding. The current model of exosome formation and release of exosomes is diagrammed in Figure 1.

Exosomes released from donor cells can be taken up by recipient cells, where an array of biological processes can be impacted in the recipient cells, including cell proliferation and differentiation, apoptosis, and the immune response (Abusamra et al., 2005; Yu et al., 2007). Exosomes have been implicated as mediators in the communication between T cells and antigen-presenting cells (APCs) at the immune synapse. Professional APCs secrete major histocompatibility complex class II (MHC II) carrying exosomes (Buschow et al., 2010), and these exosomes can stimulate antigen-specific MHC class II-restricted T cell responses (Raposo et al., 1996). Intestinal epithelial cell-derived exosomes containing αvβ6 integrin and food antigen induced dendritic cell tolerance and tolerogenic DCs in a model of tolerance induction. In addition, the presence of these intestinal epithelial cell-derived exosomes also impacted the development of antigen-specific T regulatory cells (Chen et al., 2011). Additional normal cellular processes influenced by exosomal contents include myelin membrane biogenesis and neuronal plasticity (Bakhit et al., 2011) in the central nervous system (CNS) and decreasing cholangiocyte proliferation via interactions with cholangiocyte cilia (Masyuk et al., 2010).

Exosomes may also be involved in pathogenic processes. Extracellular amyloid fibril formation, a key feature of Alzheimer’s disease, occurs at an accelerated rate in the presence of GM1 ganglioside-containing exosomes (Yuyama et al., 2008). These data suggest that targeting GM1 in exosomes may provide a mechanism to slow the rate of plaque formation. Tumor-derived exosomes may also significantly influence the development and effectiveness of anti-tumor immune responses (Rupp et al., 2011). Exposure of peripheral blood mononuclear cells (PBMCs) to exosomes isolated from ascites of ovarian cancer patients impaired the cytotoxic activity of the PBMCs in the presence of dendritic cells. In addition to containing tumor antigens, exosomes secreted from cancer cells also have been shown to contain two molecules critical to immunoregulation, PD-L1 and FasL. The presence of FasL and TRAIL in exosomes may contribute to apoptosis of cells of the immune response, thereby serving as a mechanism of tumor escape from immunosurveillance (Peng et al., 2011). For example, exosomes from plasma of cancer patients have been shown to induce T cell apoptosis (Ichim et al., 2008), reminiscent of Fas-FasL counterattack that has been described in some cancers (Alderson et al., 1995; O’Connell et al., 1998). Intercellular communication via exosomes is not limited to communications between mammalian cells. Interestingly, exosomes have been isolated from the
protozoan parasite, *Leishmania*, and these exosomes deliver protozoan proteins to macrophages in the vertebrate host. Similar to what is observed with mammalian-derived exosomes, protozoan exosomes may influence the host immune response and regulate cell signaling pathways (Silverman et al., 2010). Exosomes can also transport pathogen or virus proteins to neighboring and/or distant cells and enhance disease spread (Schorey and Bhatnagar, 2008). The infectious form of the prion protein, PrPSc, has been found in exosomes. Exosomally derived PrPSc is infectious to mice (Vella et al., 2007). This finding suggests that in humans or wildlife, exosomally derived PrPSc could serve as a source of infectious material in the host which accelerates the spread of the misfolded protein through the body. Also, because exosomes are in mucus, urine, and blood, disease spread between hosts may be enhanced by the presence of PrPSc-containing exosomes.

Exosomes are considered extracellular organelles which can affect neighboring cells following delivery of their contents into target cells (Silverman and Reiner, 2011). It has been speculated that the composition of exosomes is quite heterogenic, depending on the cellular origin of the exosome. Large-scale proteomics and phosphoproteomics studies of exosomes derived from various cell types suggest that the exosomes shuttle wide array of biologically relevant molecules, including lipids, carbohydrates, RNAs, and proteins (Schorey and Bhatnagar, 2008), as outlined in Figure 2. Detailed information regarding the contents of exosomes is available (http://dir.nhlbi.nih.gov/papers/lkem/exosome). The contents of urinary exosomes have been characterized by Knepper's group. This study identified 1132 proteins contained within the exosomes. In addition, phosphoproteomic studies identified several unique phosphorylation sites (Gonzales et al., 2009). This study, along with others, support the potential for exosomes obtained from bodily fluids to serve as biomarkers of disease development and/or progression.

**MicroRNAs ARE GENE REGULATORS AND IMPORTANT BIOMARKERS WITH THERAPEUTIC POTENTIAL**

To date, over 1000 human miRNAs have been identified and it is predicted that miRNAs control the expression of approximately 60% of all human genes (Bentwich et al., 2005; Krol et al., 2010). Accumulating data indicate that miRNAs comprise an essential component in the complex regulatory networks controlling a wide array of cellular processes, including the timing of developmental processes, cell proliferation/differentiation, apoptosis, organ development (Tiscornia and Izpisua Belmonte, 2010), and immune regulation (O’Neill et al., 2011; Zhou et al., 2011). Several excellent reviews have been recently published on these topics (O’Neill et al., 2011; Zhou et al., 2011).

![Figure 2 | Composition of exosomes](image-url)
miRNAs in exosomes and disease

Aberrant miRNA expression has been linked to the initiation and progression of certain cancers (Mencia et al., 2009). An example of a miRNA associated with cancer development (that is, an oncogenic miRNA or oncomir) is miR-21. miR-21 targets tumor suppressor genes and upregulation of miR-21 is associated with a wide variety of cancers including breast, ovaries, cervix, colon, lung, liver, brain, esophagus, prostate, pancreas, and thyroid cancers (Volinia et al., 2006; Lui et al., 2007). miRNAs are also involved in developmental processes in vertebrates. Studies utilizing genetically modified mice have demonstrated the critical requirement for miRNAs in cardiac development, as mice deficient in Dicer experience cardiac failure (Chen et al., 2008). In the CNS, the role of miRNAs in regulating neuronal development, plasticity and differentiation is under exploration (Guo et al., 2002; Gao et al., 2010). In Parkinson's disease, miR-34b and miR-34c are decreased and this decrease in expression is accompanied by a decrease in cell viability of dopaminergic neurons (Minones-Moyano et al., 2011). In Huntington's disease, both murine models of the disease as well as human tissue samples have demonstrated that RE1 silencing transcription (REST) factor, a transcriptional repressor, is not appropriately expressed, and can be found in the nucleus of neurons rather than the cytoplasm. REST dysregulation results in a wide array of miRNAs are repressed, thereby resulting in an overexpression of miRNAs in the CNS of individuals with Huntington’s disease (Johnson et al., 2008; Buckley et al., 2010).

The small size (23–24 nucleotides in length) of mature miRNA molecules makes them very attractive targets for drug development. It may be possible to restore normal levels of mature forms of dysregulated miRNAs in disease states and provide therapeutic benefits to the host by appropriately regulating the level of expression of their target genes. A variety of delivery approaches have been used to deliver miRNA precursors into cells to overexpress miRNAs of interest in vitro (Hu et al., 2009; Kota et al., 2009). In vivo studies have been performed in mice to test the therapeutic potential of miRNAs. Intranasal administration of cholesterol-conjugated anti-miR-126 to the asthmatic mice resulted in reduced airway disease characterized by decreased T-helper-2 cytokine production, decreased airway hyperresponsiveness and muscos hypersecretion, and a reduction in airway-infiltrating eosinophils and neutrophils compared to control-treated asthmatic mice (Mattes et al., 2009). Other means of delivery of antisense miRNAs has also been successful. Inhibition of miR-122 by systemic administration of a miR-122 antisense oligonucleotide reduced plasma cholesterol levels and decreased hepatic fatty acid and cholesterol synthesis rates in normal mice. Therapeutic administration of anti-miR-122 also reduced levels of triglycerides and improved hepatic steatosis in diet-induced obese mice (Esaü et al., 2006). Mice appeared healthy after one month of antisense therapy. The lack of obvious toxicity further cements the potential of miRNAs as therapeutic molecules.

The potential for use of miRNAs against cancer has been extensively studied. A recent study using plasmid–expressed miR-155 in nasopharyngeal carcinoma cells demonstrated decreased expression of manganese superoxide dismutase in miR-155 overexpressing CNE1 cells and reduced resistance to ionizing radiation (Du et al., 2011). In vivo administration of a lentivirus–expressing miR-26a resulted in inhibited tumorigenicity of nasopharyngeal cells in nude mice (Lu et al., 2011). Systemic delivery of synthetic miR-16 reduced the growth of metastatic prostate tumors by downregulating multiple cell-cycle genes in a prostate cancer xenograft model (Takekishi et al., 2010). Let-7 miRNAs are proposed to function as tumor suppressors by negatively regulating multiple oncogenes (RAS, MYC, HMGAA2) and cell-cycle promoters (CDC25A, CDK6, CCND2; Johnson et al., 2005; Mayr et al., 2007). Administration of let-7 miRNA prevented tumor formation in a mouse model of non-small cell lung cancer (Kumar et al., 2008). Intratumoral injection of synthetic let-7b miRNA significantly reduced tumor growth, induced necrotic cores in the tumors, and reduced NRAS and CDK6 expression in tumors in a mouse model of lung cancer (Trang et al., 2010). Such approaches to manipulate the expression of miRNA targets in the context of disease are currently being explored in clinical trials (Kasinski and Slack, 2011).

EXOSOMAL SHUTTLE miRNAs

A recent breakthrough in exosome biology is that RNA molecules, in particular, miRNAs, are present in these vesicles. To date, studies have demonstrated that miRNAs in exosomes can influence target cell function (Kosaka et al., 2010; Mittelbrunn et al., 2011). Hunter et al. (2008) identified miRNAs expressed in circulating plasma microvesicles from normal subjects, providing the basis for future work examining the predictive role of peripheral blood miRNA signatures in human disease, as well as defining the biological processes regulated by particular miRNAs. Koh et al. demonstrated that miRNAs are also found in the extracellular environment of human embryonic stem cell-derived mesenchymal stem cells (hES-MSC). Significant differences in expression profile of miRNAs in the intracellular and extracellular environment of hES-MSC cultures were identified. Interestingly, the let-7 miRNA family is highly expressed in both intra- and extra-cellular samples of hES-MSC (Koh et al., 2010). Advances in miRNA array techniques have provided significant advances in miRNA profiling of exosomes. Exosomes contain a substantial amount of small RNAs, but little or no ribosomal RNA compared to the levels observed in the donor cells (Valadi et al., 2007). Moreover, selective packaging of miRNAs into exosomes appears to occur, as the miRNA profiles in exosomes do not reflect the miRNA profiles observed in the parental cells (Valadi et al., 2007; Skog et al., 2008; Taylor and Gercel-Taylor, 2008; Rabinowits et al., 2009; Mittelbrunn et al., 2011). Exosomes isolated from T cells, B cells, and dendritic cells had miRNA expression profiles unique from their parent cells. The authors also demonstrated that there was antigen-driven unidirectional transfer of miRNAs from the T cell to the APC mediated by CD63+ exosomes (Mittelbrunn et al., 2011). The mechanism for the selective packaging of RNAs into exosomes is unclear. Compared to cellular RNAs, exosomal RNAs are more stable (Keller et al., 2011), and are reportedly resistant to degradation during prolonged storage and freeze/thaw cycles (Reid et al., 2011). The stability of the contents of these membrane-bound structures adds to the attractiveness of exosomes as biomarkers of cancer and other diseases.

Exosomal miRNAs have been implicated in many of exosome-mediated biological functions (Wang et al., 2010). Exosomes derived from a human (HMC-1) and mouse (MC/9) mast cell lines transport RNA to neighboring mast cells, impacting the
function of the recipient mast cells (Valadi et al., 2007; Shcorey and Bhatnagar, 2008). Impairment of exosome production reduces the transfer of miRNAs to APCs. The miRNAs transferred at the immune synapse are functional and can alter gene expression in the recipient APCs (Mittelbrunn et al., 2011). Together, the current data make a strong case for role of exosomally-derived miRNAs as mediators of cell function.

**EXOSOMAL miRNAs AS BIOMARKERS OF DISEASE**

Aberrant expression of miRNAs has been identified in numerous diseases (Table 1). In addition, exosomal miRNAs are considered as biomarkers for many pathological states (Michael et al., 2010; Ciesla et al., 2011). Exosomes from diseased individuals contain miRNAs not found in normal, healthy subjects (Taylor and Gercel-Taylor, 2008; Rabinowits et al., 2009). Many miRNAs, including virus miRNAs, are in exosomes. Nevertheless, it is unknown how exosomal miRNAs function in the recipient cells. Exosomes released from Epstein–Barr virus (EBV)-infected B95-8 LCL cells were identified in monocyte-derived dendritic cells, resulting in gene silencing in recipient cells (Pegtel et al., 2010). Furthermore, exosomal-loaded viral miRNAs suggest that exosome may serve as a vesicle to contribute to disease spread or pathogenesis (Meches et al., 2010; Pegtel et al., 2011). Interestingly, macrophages have been shown to influence the invasive-ness of breast cancer cells through exosome-mediated delivery of oncogenic miRNAs from the macrophages to the cancerous cells (Yang et al., 2011). Exosomes released from dendritic cells can fuse with the target dendritic cells and release their contents into the target cells, resulting in mRNA silencing (Montecalvo et al., 2012). A recent report from the Lim group demonstrated that miRNA-containing stroma-derived exosomes contribute to B cell quiescence. The transfer of miRNAs from bone marrow stroma to B cells may participate in dormancy of bone marrow metastases (Lim et al., 2011).

The levels of specific miRNAs in certain disease states may provide insight into disease pathogenesis and/or potential mechanisms of repair. miR-133a levels are elevated in circulating exosomes derived from injured myocardium in patients with cardiovascular diseases (Kuwabara et al., 2011). In addition, miR-133a is implicated to regulate NFATc4, a protein that contributes to cardiac hypertrophy (Li et al., 2010). Treatment with miR-133a inhibitors reduced the level of cardiac hypertrophy (Li et al., 2010).

Exosomal miRNA profiles of circulating tumor exosomes are unique from those in normal controls (Taylor and Gercel-Taylor, 2008). Because of this unique exosomal miRNA signature, screening tests utilizing circulating exosomal miRNAs as markers of disease might be used to identify tumor development. Unique miRNA profiles have been described in exosomes from patients with lung cancer, glioblastoma, and hepatocellular carcinoma (Rabinowits et al., 2009). In cancer, a variety of processes are impacted by exosomal miRNAs. While in cases such as lung adenocarcinoma, the miRNA signatures are different between cancer patients and normal controls, the exosome-loaded miRNAs are similar in nature to the miRNAs isolated from the tumors. In the case of hepatocellular carcinoma, some of the miRNAs transferred by exosomes can downregulate transforming growth factor-β activated kinase-1 (TAK1) pathway in hepatocarcinogenesis. This finding suggests that miRNAs from the exosomes may be involved in the local spread, intrahepatic metastases, or multifocal growth in hepatocellular carcinoma (Kogure et al., 2011). Liu et al. (2010) has demonstrated that tumor-derived exosomes are pivotal in promoting tumor metastasis via a proinflammatory cytokine-driven expansion of myeloid-derived suppressor cells via the MyD88 pathway. Taken together, current exosomal miRNA studies have opened a new window for the development of biomarkers for important human diseases.

**THERAPEUTIC POTENTIAL OF TARGETING EXOSOMAL miRNAs**

Due to their ability to efficiently shuttle small molecules between cells, exosomes are an extremely promising therapeutic tool for numerous diseases. Alternatively, because of the pathogenic significance of exosomal miRNAs in an array of diseases, drug development focusing on targeting the release of exosomal miRNA contents has begun. The use of exosomes as therapeutic delivery vehicles covers a wide array of diseases, including but not limited to cancer, virus-induced diseases, and parasitic diseases. Of particular note, the Wood laboratory successfully expressed Lamp2b, an exosomal membrane protein, fused to a neuron-penetrating RVG peptide in the dendritic cells isolated from mice. Exosomes released from these cells were loaded with exogenous siRNA to GAPDH by electroporation. Intravenously injected RVG-targeted exosomes delivered GAPDH siRNA specifically to neurons, microglia, oligodendrocytes in the brain, resulting in a specific gene knockdown (Alvarez-Erviti et al., 2011). Akao et al. reported that chemically modified miRNAs (i.e., miR-143BPs) are detectable in exosomes secreted from THP-1 macrophages following miR-143BP transfection. More importantly, increased miR-143BP levels were detected in the serum, tumor, and kidney of the host animals when the mice were intravenously injected with the THP-1 macrophages transfected with miR-143BP (Akao et al., 2011). These data suggest that manipulating exosomal miRNAs ex vivo may be an efficient tool to deliver miRNAs to target specific organs. Exosomes have also been utilized successfully to deliver siRNAs to specific cell types in vivo in mice (van den Boorn et al., 2011). Thus far, studies on manipulation of exosomal miRNAs are primarily in animal models and the clinical application of this work is unclear, although it is obvious that, (1) exosomes could serve as targets of therapy and (2), delivery miRNAs to target cells through exosomes is feasible. Therefore, functional manipulation of miRNAs in exosomes and in vivo delivery of exosomal miRNAs would be novel targets for therapeutic intervention for a variety of human diseases. With the advance of technology that allows us to manipulate the miRNA contents in exosomes as well as exosomal membrane proteins, the future studies on exosomal miRNAs will benefit all patients by providing efficient diagnosis and disease-specific therapy.

**CONCLUSION AND PERSPECTIVES**

Currently, ExoCarta (Version 3.1) contains information on 11,261 protein entries, 2375 mRNA entries, and 764 miRNA entries that were obtained from 134 exosomal studies (Mathivanan et al., 2011). There are several advantages for the use of exosomes/microvesicles to deliver information to a target cell.
Table 1 | Exosomal miRNAs as potential biomarkers and therapeutic targets

| Exosomal miRNAs | Pathological conditions | Potential pathological significance | Reference |
|-----------------|-------------------------|-----------------------------------|-----------|
| miR-23a, 132, 181a, 215, 362-5p, 375, 512a-3p, 523 | Ovarian FF from estrous mares | Biomarker; oocyte growth and maturation | da Silveira et al. (2012) |
| miR-20b, 22, 23b, 24, 135a, 135b, 152, 181c, 197, 223, 320a, 323-5p, 378, 433 | Ovarian FF from estrous mares | Biomarker; oocyte growth and maturation | da Silveira et al. (2012) |
| miR-25, 188-5p, 192, 320b, 320c | Ovarian FF from estrous mares | Biomarker; oocyte growth and maturation | da Silveira et al. (2012) |
| miR-223 | Human MDM and breast cancer cell lines, SKBR3 and MDA-MB-231 | Regulate the invasiveness of breast cancer cells | Yang et al. (2011) |
| miR-584, 517c, 378, 520f, 451, 518d, 215, 376a, 133b, 367 | HCC Hep3B, Human HCC cell line | Multiple oncogenic or tumor suppressor genes | Kogure et al. (2011) |
| miR-142-5p, 15a, 129, 101, 296, 145, 361, 23b, 23a, 100, 99b, 324-5p, 30a-5p, 7, 15b, 27b, 615, 218, 328, 10a, 222, 342, 125a, 572, 149, 30d, 451, 25, let-7a, let-7c, let-7b, let-7f, let-7g | Human CD105 + and CD105 - renal carcinomas cells | Angiogenic switch and coordinating metastatic diffusion, downregulated in CD105 + exosome | Grange et al. (2011) |
| miR-200c, 146a, 184, 335, 646, 449b, 650, 141, 183, 19b, 29c, 182, 19a, 92, 301, 151, 130b, 22, 186, 140, 486, 26b, 29a | Patient, acute myocardial infarction | Angiogenic switch and coordinating metastatic diffusion, upregulated in CD105 + exosome | Grange et al. (2011) |
| miR-223 | Human CD105 + and CD105 - renal carcinomas cells | Angiogenic switch and coordinating metastatic diffusion, downregulated in CD105 + exosome | Grange et al. (2011) |
| miR-1, 133a | Patient, acute myocardial infarction | Acute myocardial infarction | Kuwabara et al. (2011) |
| miR-16, 27a, 146b and 222 | Human CD105 + and CD105 - renal carcinomas cells | Lipid storage (metabolic diseases) | Müller et al. (2011) |
| EBV miRNAs | Human nasopharyngeal carcinoma cells | Manipulate the tumor microenvironment and influence neighboring cell signaling | Meckes et al. (2010) |
| Let-7 miRNA family | Human embryonic kidney cell line | Tumorigenesis and metastasis | Ohshima et al. (2010) |
| miR-486, 328, 183, 32, 574, 27b, 222, 197, 151, 17-5p, 199a*, 133b, 320, 96, 103 | PBMC | Regulate homeostasis of hematopoietic cells and of metabolic function | Hunter et al. (2008) |
| miR-219, 579, 515-5p, 29c, 15b, 483-5p, 29a, 22, 23a, 16, 30d, 302c, 452, 646, 488, 181c | A549, Human lung adenocarcinoma epithelial cell line | Cell–cell communication | Wang et al. (2010) |
| miR-204, 219, 483-5p, 26b, 16, 30d, 22, 646, 145, 29a, 23a, 373, 199b, 342, 29a | HepG2, Human hepatocellular liver carcinoma cell line | Cell–cell communication | Wang et al. (2010) |
| miR-517a, 21 | BeWo, Human placenta choriocarcinoma cell line | Signal transduction | Luo et al. (2009) |
| let-7b, let-7c*, miR-128, 150*, 17, 1908, 212, 27b*, 29b, 29c, 335, 379*, 433, 454, 483-3p, 584, 621, 652, 760, 888* | Parotid saliva from Sjogren’ syndrome patient and normal volunteer | Biomarkers of the diagnosis and prognosis of various salivary gland pathologies | Michael et al. (2010) |
| let-7b, miR-150*, 23a*, 27b*, 29b, 29c, 335, 379*, 433, 454, 483-3p, 584, 621, 652, 760, 888*, miRPlus_17824, 17841, 17848, 17858, 17824, 17848, 17858, 42487, 42526 | Parotid saliva from Sjogren’ syndrome patient and normal volunteer | Biomarkers of the diagnosis and prognosis of various salivary gland pathologies | Michael et al. (2010) |
| miR-16, 21, 155 | HEK293, Human embryonic kidney cell line | Biomarkers of the diagnosis and prognosis of various salivary gland pathologies | Michael et al. (2010) |
| Let-7a, miR-15b, 16, 19b, 21, 26a, 27a, 92, 93, 320, 20 | Patient with ovarian disease; primary ovarian tumor cell | Diagnostic information and aid in therapeutic decisions for cancer patients | Skog et al. (2008) |
| miR-214, 140, 147, 135b, 205, 150, 149, 370, 206, 197, 634, 485-5p, 612, 608, 202, 373, 324-3p, 103, 593, 574, 483, 527, 603, 649, 18a, 595, 193b, 642, 557, 801, 1-7e | Patient with ovarian disease; primary ovarian tumor cell | Diagnostic information and aid in therapeutic decisions for cancer patients | Skog et al. (2008) |

Aberrant expression of exosomal miRNAs has been found under different pathological conditions, indicating that miRNAs could be potential biomarkers and therapeutic targets. This table describes exosomal miRNAs identified under different pathological conditions and their potential pathological significance. FF, follicular fluid; HCC, hepatocellular carcinoma; PBMC, peripheral blood mononuclear cells; MDM, human monocyte-derived macrophage.
Exosomes can shuttle miRNAs and miRNAs directly to recipient cells which increases the likelihood that this information will alter the function of target cells. The release of exosomes allows cell–cell communication regardless of the distance between the cells. Exosomes have been identified in body fluids and blood, indicating that this exchange of information between organs may occur via exosomes (Qazi et al., 2010). Additionally, exosomes may contain cell-specific factors that allow the exosomes to target specific cells for delivery of the exosomal contents (proteins, miRNAs, miRNAs, and DNAs) to recipient cells with a high degree of efficiency. Exosomal miRNAs may reflect disease specific-aberrations. Emerging evidence supports the hypothesis that disease diagnosis can occur by examining levels of miRNA in exosomes isolated from body fluids. Finally, manipulation of the miRNAs within exosomes may provide an effective tool to target therapy to specific cells and organs.

ACKNOWLEDGMENTS

This work was partially supported by National Natural Science Foundation of China No. 31101809 (to Guoku Hu), the Institute of Health AI095532, and Tobacco Settlement Foundation of Nebraska LB506 and CU LB595 (to Xian-Ming Chen).

REFERENCES

Hu et al. miRNAs in exosomes and disease

www.frontiersin.org

April 2012 | Volume 3 | Article 56 | 7
anti-tumor immunity. *Oncol. Rep.* 25, 749–762.

Qazi, K. R., Torregrosa Paredes, P., Dahlberg, B., Grunewald, J., Eklund, A., and Gabrielson, S. (2010). Proinflammatory exosomes in bronchoalveolar lavage fluid of patients with sarcoidosis. *Thorax* 65, 1016–1024.

Rabinowits, G., Gercel-Taylor, C., Day, J. M., Taylor, D. D., and Kloecker, G. H. (2009). Exosomal microRNA: a diagnostic marker for lung cancer. *Clin. Lung Cancer* 10, 42–46.

Raposo, G., Nijman, H. W., Stoorvogel, W., Liefdendekker, R., Harding, C. V., Melief, C. J., and Geuze, H. J. (1996). B lymphocytes secrete antigen-presenting vesicles. *J. Exp. Med.* 183, 1161–1172.

Record, M., Subra, C., Silvente-Poirot, C., Shirvani, O., Fang, Y., and Wang, A. (2012). Circulating miRNAs in exosomes and disease. *Front. Gene.* 3, 15.

Silverman, J. M., Clos, J., De’oliveira, C. C., Shrivani, O., Fang, Y., Wang, C., Foster, L. J., and Reiner, N. E. (2010). An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages. *J. Cell. Sci.* 123, 842–852.

Silverman, J. M., and Reiner, N. E. (2011). Exosomes and other microvesicles in infection biology: organelles with unpicipitated nophotypes. *Cell. Microbiol.* 13, 1–9.

Skog, J., Wurdinger, T., Van Rijn, S., Meijer, D. H., Gianche, L., Sana-Esteves, M., Curry, W. T., Jr., Carter, B. S., Krichovsky, A. M., and Breaufeld, X. O. (2008). Glialbltabama microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat. Cell Biol.* 10, 1470–1476.

Sudhof, T. C., and Rothman, J. E. (2009). Membrane fusion: grappling with SNARE and SM proteins. *Science* 323, 474–477.

Sutton, R. B., Fasahauer, D., Jahn, R., and Brunger, A. T. (1998). Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. *Nature* 395, 347–353.

Takeshita, F., Patrawala, L., Osaki, M., Takashashi, R. U., Yamamoto, Y., Kosaka, N., Kawamata, M., Kelnar, K., Bader, A. G., Brown, D., and Ochiya, T. (2010). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. *Mol. Ther.* 18, 181–187.

Taylor, D. D., and Gercel-Taylor, C. (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol. Oncol.* 110, 13–21.

Thery, C. (2011). Exosomes: secreted vesicles and intercellular communications. *Fl1000 Biol. Rep.* 3, 15.

Thery, C., Dohn, M., and Brunner, G., Marme, F., Sultmann, J. C., Ehehalt, R., Fogel, M., Moldenhauer, G., and Brunger, A. T. (1998). Crystral structure of a SNARE complexes involved in synaptic exocytosis at 2.4 A resolution. *Nature* 395, 347–353.

Tiscornia, G., and Izipisu Belmonte, J. C. (2010). MicroRNAs in embryonic stem cell function and fate. *Genes Dev.* 24, 2732–2741.

Trang, P., Medina, P. P., Wiggins, J. F., Ruffino, L., Kelner, K., Omotola, M., Homer, R., Brown, D., Bader, A. G., Weidhans, J. B., and Slack, F. J. (2010). Regression of murine lung tumors by the let-7 microRNA. *Oncogene* 29, 1580–1587.

Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., and Lovall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* 9, 654–659.

van den Boorn, J. G., Schlee, M., Coch, C., and Hartmann, G. (2011). siRNA delivery with exosome nanoparticles is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* 9, 654–659.

Vella, L. I, Sharples, R. A., Lawson, V. A., Masters, C. L., Cappai, R., and Hill, A. F. (2007). Packaging of prions into exosomes is associated with a novel pathway of PrP processing. *J. Pathol.* 211, 582–590.

Volinia, S., Calin, G. A., Liu, C. G., Ambra, S., Cammmino, A., Petrozza, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, R. L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negrini, M., Harris, C. C., and Croce, C. M. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc. Natl. Acad. Sci. U.S.A.* 103, 2257–2261.

Wang, K., Zhang, S., Weber, J., Baxter, D., and Galas, D. J. (2010). Export of microRNAs and microRNA-protective protein by mammalian cells. *Nucleic Acids Res.* 38, 7248–7259.

Yang, M., Chen, J., Su, F., Yu, B., Lin, L., Liu, Y., Huang, J. D., and Song, E. (2011). Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. *Mol. Cancer* 10, 117.

Yu, S., Liu, C., Su, K., Wang, J., Liu, Y., Zhang, L., Li, C., Cong, X., Kimberly, R., Grizzle, W. E., Falkson, C., and Zhang, H. G. (2007). Tumor exosomes inhibit differentiation of bone marrow dendritic cells. *J. Immunol.* 178, 6867–6875.

Yuyama, K., Yamamoto, N., and Yanaigawa, K. (2008). Accelerated release of exosome-associated GM1 ganglioside (GM1) by endocytic pathway abnormality: another putative pathway for GM1-induced amyloid fibril formation. *J. Neurochem.* 105, 217–224.

Zhou, R., O’Hara, S. P., and Chen, X. M. (2011). MicroRNA regulation of innate immune responses in epithelial cells. *Cell. Mol. Immunol.* 8, 371–379.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 10 January 2012; accepted: 27 March 2012; published online: 20 April 2012.

Citation: Hu G, Drescher KM and Chen X-M (2012) Exosomal miRNAs: biological properties and therapeutic potential. *Front. Genet.* 3:6. doi: 10.3389/fgene.2012.00036

This article was submitted to Frontiers in Non-Coding RNA, a specialty of Frontiers in Genetics.

Copyright © 2012 Hu, Drescher and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

www.frontiersin.org